Jill Marie Broadfoot - 09 Jan 2026 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Role: Chief Financial Officer
Signature: /s/ Nancy E. Denyes, attorney-in-fact
Issuer symbol: ATYR
Transactions as of: 09 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 09 Jan 2026, 17:42:27 UTC
Previous filing: 06 Jan 2026
Next filing: 04 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Broadfoot Jill Marie	Chief Financial Officer	10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO	/s/ Nancy E. Denyes, attorney-in-fact	09 Jan 2026	0001305178

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ATYR	Common Stock						35,104	09 Jan 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATYR	Employee Stock Option (right to buy)	Award	$0	+412,500		$0.000000	412,500	09 Jan 2026	Common Stock	412,500	$0.7127	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 841 shares acquired on May 15, 2025 and 2,500 shares acquired on November 14, 2025 under the Company's 2015 Employee Purchase Plan.
F2	The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning February 9, 2026, such that this option will be fully exercisable on January 9, 2029. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.